Original articleThe comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study☆
Section snippets
Methods
The study was commenced as a single-site, prospective, randomized, and single-masked clinical trial. Informed consent was obtained from all patients, and the research was begun after obtaining approval from the Institutional Review Board of the Louisiana State University Health Sciences Center. The research was carried out according to the tenets of the Declaration of Helsinki. All study medications were dispensed in coded bottles. The examiner (A.M.A.) was masked as to the medication used by
Results
A total of 32 patients were enrolled in the study. Four patients were discontinued for administrative reasons. Eight patients in group 1, nine patients in group 2, and 11 patients in group 3 concluded the whole study period. None of the above discontinued patients reported adverse effects that could be related to the medications used in this study.
Group 1 contained five female and three male patients (mean age, 51.2 ± 12.4 SD). Five female and four male patients constituted group 2 (mean age,
Discussion
The most important results of this study were that treatment with TSD significantly improved the ocular signs and symptoms of moderate-to-severe dry eye patients, and these improvements were associated with reduction of HLA-DR+ cells and an increase of PAS+ cells in conjunctival impression cytology specimens. However, ATS alone or ATS plus NSAID did not change these parameters. Keratoconjunctivitis sicca is an autoimmune disease that involves not only the lacrimal gland but also the whole
References (25)
- et al.
Expression of Fas antigen on keratocytes in vivo and induction of apoptosis in cultured keratinocytes
J Dermatol
(1994) - et al.
Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease
Ophthalmology
(2000) - et al.
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group
Ophthalmology
(2000) - et al.
Topical non-preserved methylprednisolone therapy of keratoconjunctivitis sicca in Sjogren’s syndrome
Ophthalmology
(1999) - et al.
Modulation of MHC class II expression in human cells by dexamethasone
Cell Immunol
(1995) - et al.
Adenovirus-mediated gene transfer to the ocular surface epithelium
Exp Eye Res
(1998) - et al.
Flow cytometry in impression cytology specimensa new method for evaluation of conjunctival inflammation
Invest Ophthalmol Vis Sci
(1997) - et al.
Expression of Fas-Fas ligand antigens and apoptotic marker APO 2.7 by the human conjunctival epitheliumpositive correlation with class II HLA DR expression in inflammatory ocular surface disorders
Exp Eye Res
(1998) - et al.
Expression of CD 40 and CD 40 ligand in the human conjunctival epithelium
Invest Ophthalmol Vis Sci
(2000) Current aspects in organ transplantations
Schweiz Rundsch Med Prax
(1989)
Cyclic 3.5 adenosine monophosphate and cyclosporine A inhibit cellular proliferation and serine/threonine protein phosphatase activity in putuitary cells
Endocrinology
Analysis of topical cyclosporine treatment of patients with dry eye syndromeeffect on conjunctival lymphocytes
Arch Ophthalmol
Cited by (0)
- ☆
InternetAdvance publication at ajo.com April 24, 2003.